Scancell Holdings Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 22
Employees
  • Stock Symbol
  • SCLP
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.31
  • (As of Friday Closing)

Scancell Holdings General Information

Description

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
LON
Primary Office
  • John Eccles House
  • Robert Robinson Avenue, Oxford Science Park
  • Oxford OX4 4GP
  • England, United Kingdom
+44 01865 000000

Scancell Holdings Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Scancell Holdings Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.31 $0.31 $0.13 - $0.40 $251M 815M 741K -$0.02

Scancell Holdings Financials Summary

In Thousands,
USD
TTM 31-Oct-2020 FY 2020 30-Apr-2020 FY 2019 30-Apr-2019 FY 2018 30-Apr-2018
EV 125,827 39,829 16,698 56,349
Revenue 0 0 0
EBITDA (10,189) (8,523) (8,749) (6,568)
Net Income (8,752) (6,967) (7,339) (5,606)
Total Assets 41,166 10,996 13,632 20,154
Total Debt 4,558 161 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Scancell Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Scancell Holdings‘s full profile, request access.

Request a free trial

Scancell Holdings Executive Team (10)

Name Title Board Seat Contact Info
Lindy Durrant Ph.D Chief Executive Officer
Keith Green Director, Finance & Administration
John Chiplin Ph.D Executive Chairman & Board Member
Richard Goodfellow Ph.D Board Member
Sally Adams Board Member
You’re viewing 5 of 10 executive team members. Get the full list »

Scancell Holdings Board Members (11)

Name Representing Role Since
John Chiplin Ph.D Scancell Holdings Executive Chairman & Board Member 000 0000
Martin Diggle Self Board Member 000 0000
Matthew Frohn Ph.D Self Board Member 000 0000
Richard Goodfellow Ph.D Scancell Holdings Board Member 000 0000
Sally Adams Scancell Holdings Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Scancell Holdings Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Scancell Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Scancell Holdings‘s full profile, request access.

Request a free trial

Scancell Holdings Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 0000 01-Apr-2018 000000000 00000 00 Buildings and Property
To view Scancell Holdings’s complete investments history, request access »